🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07063550
Active, not recruiting Observational

Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer

NCT07063550 · tracked via the Priya Life Science China tracker
Sponsor
Dong Peng
Phase
Observational
Started
2024-12-01
Last updated
2025-07-14

Condition(s) studied

Colorectal Cancer (MSI-H)Microplastic Exposure

Investigational drug(s) / intervention(s)

exposure to microplastic

exposure to microplastic: Microplastic content in cancerous and paracancerous tissues

Study summary

The objective of this study is to identify and characterize microplastics present in peritumoral and intratumoral tissues of colorectal cancer patients, and to investigate their associations with gut microbiome composition and metabolic profiles. By integrating microplastic analysis with metagenomic and metabolomic data, we aim to explore the potential impact of environmental microplastic exposure on tumor microenvironment alterations, microbial dysbiosis, and metabolic reprogramming in colorectal cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Adult patients (≥18 years old) with histologically confirmed colorectal adenocarcinoma. * Undergoing elective radical colorectal cancer resection at the study hospital. * No prior chemotherapy, radiotherapy, or targeted therapy before surgery. * Availability of both tumor tissue and adjacent normal (peritumoral) tissue samples during surgery. * Willingness to provide stool and/or blood samples for metagenomic and metabolomic analysis. * Ability to understand the study procedures and provide written informed consent. Exclusion Criteria: * Patients with a history of other malignancies within the past 5 years. * Emergency surgery due to obstruction, perforation, or bleeding. * Inadequate sample quality or volume for microplastic, metagenomic, or metabolomic analysis. * Presence of chronic inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis). * Use of antibiotics, probiotics, or prebiotics within 4 weeks prior to sample collection. * Pregnant or breastfeeding women. * Refusal or inability to provide informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality

More Dong Peng trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07063550 on ClinicalTrials.gov ↗ ← All trials in China